Millennium: The Takeda Oncology Company
United States
281 articles about Millennium: The Takeda Oncology Company
-
On March 31, Cambridge, Massachusetts-based Nuvalent announced that Anna Protopapas has been appointed as Chair of its Board of Directors.
-
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
-
Millennium: The Takeda Oncology Company Release: FDA Approves VELCADE® (Bortezomib) For Injection For Previously Untreated Patients With Mantle Cell Lymphoma
10/9/2014
-
Millennium: The Takeda Oncology Company Release: FDA Approves VELCADE® (Bortezomib) Retreatment In Patients With Multiple Myeloma
8/11/2014
-
Ex-Millennium: The Takeda Oncology Company CEO to Head EnVivo Pharmaceuticals, Inc.
7/12/2013
-
Millennium: The Takeda Oncology Company Release: Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients With M
4/8/2013
-
Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer
3/29/2013
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
1/24/2013
-
Multiple Myeloma Research Foundation (MMRF) Names Millennium: The Takeda Oncology Company Collaborator of the Year
1/23/2013
-
Infinity Pharmaceuticals Inc. Pays Millennium: The Takeda Oncology Company $15 Million
12/27/2012
-
Millennium: The Takeda Oncology Company Reports Positive Velcade Trial Data
12/10/2012
-
VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium: The Takeda Oncology Company Pipeline Agents to be Featured at American Society of Hematology Annual Meeting
11/6/2012
-
Millennium: The Takeda Oncology Company is #1 in Boston Globe Ranking of Top Largest Employer
11/5/2012
-
Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma
11/1/2012
-
Seattle Genetics, Inc. Gets Conditional OK for ADCETRIS&0174 in EU; Triggers $25 Million Milestone Payment From Millennium: The Takeda Oncology Company
10/31/2012
-
Millennium: The Takeda Oncology Company Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis
10/19/2012
-
Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. Highlight Data From ADCETRIS® (Brentuximab Vedotin) Trial in Patients With Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma
10/1/2012
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Complete Enrollment in Phase 3 AETHERA Trial of ADCETRIS® for Post-Transplant Patients With Hodgkin Lymphoma
9/25/2012
-
Actinium Pharmaceuticals, Inc. Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year
9/21/2012
-
Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Co. Ltd. Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe
7/20/2012